155 related articles for article (PubMed ID: 15577149)
1. [Measures for osteoporosis in the dermatological field--vitamin D3 and bisphosphonate].
Okada N
Clin Calcium; 2004 Oct; 14(10):145-9. PubMed ID: 15577149
[TBL] [Abstract][Full Text] [Related]
2. [Active vitamin D3 therapy for gulucocorticoid-induced osteoporosis].
Nakayama H
Clin Calcium; 2006 Jul; 16(7):1201-7. PubMed ID: 16816482
[TBL] [Abstract][Full Text] [Related]
3. [The clinical benefits to bone mineral density were shown by cyclical oral etidronate administration in steroid induced osteoporosis].
Nakamura T; Maekawa S; Morinobu S; Morinobu A; Koshiba M; Yamauchi M; Sugimoto T; Kumagai S
Ryumachi; 2002 Aug; 42(4):666-75. PubMed ID: 12355861
[TBL] [Abstract][Full Text] [Related]
4. Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial.
Stoch SA; Saag KG; Greenwald M; Sebba AI; Cohen S; Verbruggen N; Giezek H; West J; Schnitzer TJ
J Rheumatol; 2009 Aug; 36(8):1705-14. PubMed ID: 19487264
[TBL] [Abstract][Full Text] [Related]
5. [Efficiency of calcium and vitamin D3 in the treatment of steroid osteoporosis in patients with hormone dependent bronchial asthma].
Ememl'ianov AV; Shevelev SE; Murzin BA; Amosov VI
Ter Arkh; 1999; 71(11):68-9. PubMed ID: 10626343
[TBL] [Abstract][Full Text] [Related]
6. [Activate vitamin D3 or bisphosphonate in glucocorticoid-induced osteoporosis].
Imanishi Y; Nishizawa Y
Clin Calcium; 2006 Nov; 16(11):1844-50. PubMed ID: 17079851
[TBL] [Abstract][Full Text] [Related]
7. [Evidence and utility of etidronate for the treatment of osteoporosis].
Takada J; Iba K; Yamashita T; Yoshizaki T
Clin Calcium; 2008 Oct; 18(10):1427-33. PubMed ID: 18830039
[TBL] [Abstract][Full Text] [Related]
8. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
Gallagher JC; Rosen CJ; Chen P; Misurski DA; Marcus R
Bone; 2006 Dec; 39(6):1268-75. PubMed ID: 16884968
[TBL] [Abstract][Full Text] [Related]
9. Effect of bisphosphonate treatment on bone mineral density in patients with thalassaemia major.
Skordis N; Ioannou YS; Kyriakou A; Savva SC; Efstathiou E; Savvides I; Christou S
Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():144-8. PubMed ID: 19337169
[TBL] [Abstract][Full Text] [Related]
10. Alendronate in combination with calcium and vitamin D prevents bone loss after orthotopic liver transplantation: a prospective single-center study.
Millonig G; Graziadei IW; Eichler D; Pfeiffer KP; Finkenstedt G; Muehllechner P; Koenigsrainer A; Margreiter R; Vogel W
Liver Transpl; 2005 Aug; 11(8):960-6. PubMed ID: 16035083
[TBL] [Abstract][Full Text] [Related]
11. [Treatment of osteoporosis combined with a bisphosphonate and vitamin D3].
Kobayashi S; Shiraki M; Takaoka K
Nihon Rinsho; 2004 Feb; 62 Suppl 2():461-5. PubMed ID: 15035171
[No Abstract] [Full Text] [Related]
12. Prevalence of evaluation and treatment of glucocorticoid-induced osteoporosis in men.
Cruse LM; Valeriano J; Vasey FB; Carter JD
J Clin Rheumatol; 2006 Oct; 12(5):221-5. PubMed ID: 17023807
[TBL] [Abstract][Full Text] [Related]
13. [Guidelines for the treatment of glucocorticoid-induced osteoporosis and their future problems].
Soen S
Clin Calcium; 2006 Nov; 16(11):1788-96. PubMed ID: 17079844
[TBL] [Abstract][Full Text] [Related]
14. Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV.
McComsey GA; Kendall MA; Tebas P; Swindells S; Hogg E; Alston-Smith B; Suckow C; Gopalakrishnan G; Benson C; Wohl DA
AIDS; 2007 Nov; 21(18):2473-82. PubMed ID: 18025884
[TBL] [Abstract][Full Text] [Related]
15. [Medical prophylaxis and treatment of steroid induced osteoporosis].
Rødevand E; Mikkelsen K; Nordvåg BY; Haga HJ; Førre Ø; Johnsen V; Kvien TK
Tidsskr Nor Laegeforen; 2005 Jun; 125(12):1643-5. PubMed ID: 15976829
[TBL] [Abstract][Full Text] [Related]
16. [Vitamin D and calcium for the treatment of osteoporosis].
Inoue D
Nihon Rinsho; 2009 May; 67(5):967-74. PubMed ID: 19432118
[TBL] [Abstract][Full Text] [Related]
17. [Evidence for efficacy of active vitamin D3 as an anti-osteoporotic drug].
Inoue D
Clin Calcium; 2008 Oct; 18(10):1469-75. PubMed ID: 18830044
[TBL] [Abstract][Full Text] [Related]
18. [Risk of osteoporosis in steroid therapy. When and how to counter the risk].
Kirchgatterer A; Aschl G; Hinterreiter M; Knoflach P
MMW Fortschr Med; 2001 Jun; 143(25):37-9. PubMed ID: 11468995
[TBL] [Abstract][Full Text] [Related]
19. Alendronate/vitamin D3 70 mg/2800 IU with and without additional 2800 IU vitamin D3 for osteoporosis: results from the 24-week extension of a 15-week randomized, controlled trial.
Binkley N; Ringe JD; Reed JI; Ljunggren O; Holick MF; Minne HW; Liu M; Lamotta A; West JA; Santora AC
Bone; 2009 Apr; 44(4):639-47. PubMed ID: 19185560
[TBL] [Abstract][Full Text] [Related]
20. Alendronate and indapamide alone or in combination in the management of hypercalciuria associated with osteoporosis: a randomized controlled trial of two drugs and three treatments.
Giusti A; Barone A; Pioli G; Girasole G; Siccardi V; Palummeri E; Bianchi G
Nephrol Dial Transplant; 2009 May; 24(5):1472-7. PubMed ID: 19075192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
